Brief: Cellect Biotechnology And Canndoc To Enter Into Strategic Pharma Grade Cannabis Commercial Deal For Reduction In Opioid Usage

Quoin Pharmaceuticals

04/03/2020 13:07

March 4 (Reuters) - Cellect Biotechnology Ltd  APOP.O :
    * CELLECT BIOTECHNOLOGY AND CANNDOC LTD. TO ENTER INTO
STRATEGIC
PHARMA GRADE CANNABIS COMMERCIAL DEAL FOR REDUCTION IN OPIOID
USAGE
    * CELLECT BIOTECHNOLOGY LTD - CELLECT WILL LEAD DEVELOPMENT
OF
FUTURE GENERATIONS OF PHARMA GRADE MEDICAL CANNABIS PRODUCTS
    * CELLECT BIOTECHNOLOGY - CELLECT WILL ACQUIRE FROM CANNDOC
ALL
RIGHTS TO USE OF CANNDOC PRODUCTS FOR REDUCTION OF OPIOID USAGE
    * CELLECT BIOTECHNOLOGY LTD - CELLECT WILL HAVE OPTION TO
EXTEND
AGREEMENT FOR AN ADDITIONAL PERIOD OF 5 YEARS, UNTIL 2029
    * CELLECT BIOTECHNOLOGY - CELLECT WILL ISSUE TO CANNDOC 1
MILLION
ADRS OF CELLECT'S SHARE CAPITAL ON PARTIALLY DILUTED BASIS

Source text for Eikon:  ID:nPn2zGLwNa 
Further company coverage:  APOP.O 

 ((Reuters.Briefs@thomsonreuters.com;))